---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-046707"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:43:59.665134+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma approved for dual listing on Upstream; trading starts Nov 26

## Summary
- Approved to dual list shares on Upstream, a MERJ Exchange market and global trading app.
- Trading begins November 26, 2024 at 10:00 a.m. ET under ticker 'KAPA'.
- Dual listing aims to access global investor base outside U.S., unlock liquidity, enhance price discovery.
- CEO John Yu says listing supports shareholder value and advancement of lead drug ENV105 in cancer trials.

## SEC filing metadata
- accession: 0001493152-24-046707
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/0001493152-24-046707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315224046707/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-046707
- JSON: https://secwatch.observer/filing/0001493152-24-046707.json
- Plain text: https://secwatch.observer/filing/0001493152-24-046707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.